Bi-allelic TPP1 variants in neuronal ceroid lipofuscinosis 2: clinical findings from an Iranian cohort of 20 patients, founder effect, and in silico analyses
Human Genetics · 2026
DOI: 10.1007/s00439-025-02812-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Genetics, 2026. Verfasst von Sajjad Biglari und 56 weiteren Autor:innen. Beteiligte Einrichtung: Farin Genetics Laboratory, Tehran, Iran. S1369b@yahoo.com. Hauptthemen laut MEDLINE: Neuronal Ceroid-Lipofuscinoses, Dipeptidyl-Peptidases and Tripeptidyl-Peptidases, Founder Effect, Aminopeptidases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 63 Literaturangaben.
Abstract (Originalsprache)
Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) is a rare neurodegenerative disorder. It exhibits an autosomal recessive inheritance pattern and is attributable to pathogenic variants in the TPP1 gene. This study sought to identify and characterize TPP1 variants in eighteen Iranian consanguineous families affected by CLN2 disease. A developmental history, brain imaging, and neurological evaluation were conducted. Exome sequencing (ES) was conducted on the probands' DNA. ACMG criteria were used to evaluate pathogenicity, as well as several in silico prediction techniques, protein stability algorithms, and homozygosity mapping. Three-dimensional protein modeling was used to assess structural effects. Shared haplotypes have been determined to assess possible founder alleles and the time to the most recent common ancestor (MRCA). We found twelve different TPP1 bi-allelic variants, six of which had never been reported before, two of which were only listed in ClinVar, and four of which were known to be pathogenic alleles. It contained four various types of variants: missense (33%), nonsense (25%), frameshift (25%), and splice-site (17%). The majority of the variants were found within the peptidase S53 domain. All new alleles were found in the "rare-plus-high-CADD" range, which is higher than the gene-specific mutation significance cutoff (MSC). The recurrence of c.729C > G (p.Phe243Leu) in several families, along with a common ~ 2.86 Mb homozygous haplotype and an estimated most recent common ancestor (MRCA) of ~ 16.7 generations (~ 450 years), strongly indicates a founder effect. Psychomotor regression was universal in clinical settings, seizures usually started between the ages of 3 and 5, and 40% of patients died before the age of 10. No affected patients received enzyme replacement therapy due to financial constraints. This study represents the most extensive Iranian series of CLN2 to date, broadens the TPP1 mutational spectrum with six novel alleles, and reveals a significant founder effect. The results improve genotype–phenotype correlations and show how important it is to do carrier screening that is specific to each population and to make enzyme replacement therapy available quickly in regions with limited funding. ES proved critical for accurate CLN2 diagnosis, precise genetic counseling, and revealing gaps in the availability of broad treatment for rare disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Farin Genetics Laboratory, Tehran, Iran. S1369b@yahoo.com.
- Department of Genetics, Faculty of Biological Sciences and Technology, Shahid Ashrafi Esfahani University, Isfahan, Iran.
- Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
- Molecular Medicine Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
- Dr. Nikuei Genetic Center, Bandar Abbas, Iran.
- Farin Genetics Laboratory, Tehran, Iran.
Zitieren
APA
Biglari, S., Rezaei, H., Asadollahzadeh, E., Nikuei, P., Sahraian, M. A., Sohanforooshan Moghaddam, A., Vahidnezhad, H., Youssefian, L., Galehdari, H., Seifi, T., Chamanrou, N., Heydaran, S., Parvas, S., Shariati, G., Saberi, A., Hamid, M., Zareei, T., Tabasi, S., Ranjbar, S., …, & Ghayoor Karimiani, E. (2026). Bi-allelic TPP1 variants in neuronal ceroid lipofuscinosis 2: clinical findings from an Iranian cohort of 20 patients, founder effect, and in silico analyses. Human Genetics. https://doi.org/10.1007/s00439-025-02812-3
Vancouver
Biglari S, Rezaei H, Asadollahzadeh E, Nikuei P, Sahraian MA, Sohanforooshan Moghaddam A, et al. Bi-allelic TPP1 variants in neuronal ceroid lipofuscinosis 2: clinical findings from an Iranian cohort of 20 patients, founder effect, and in silico analyses. Human Genetics. 2026. doi:10.1007/s00439-025-02812-3
BibTeX
@article{Biglari2026,
author = {Biglari, Sajjad and Rezaei, Halimeh and Asadollahzadeh, Elnaz and Nikuei, Pooneh and Sahraian, Mohammad Ali and Sohanforooshan Moghaddam, Atefeh and Vahidnezhad, Hassan and Youssefian, Leila and Galehdari, Hamid and Seifi, Tahere and Chamanrou, Niloofar and Heydaran, Sogand and Parvas, Sahere and Shariati, Gholamreza and Saberi, Alihossein and Hamid, Mohammad and Zareei, Taher and Tabasi, Shahrzad and Ranjbar, Sina and Khademi, Gholamreza and Golmakani, Hasan and Hashemi, Narges and Akhavan, Hossein and Naseri, Maryam and Donyadideh, Nahid and Barkhordari, Ehsan and Beiraghi Toosi, Mehran and Arabi, Samaneh and Heidari, Negar and Eghbal, Fatemeh and Badpar, Hasan and Saeidinia, Amin and Imannezhad, Shima and Bagheri, Sepideh and Lotfi, Mojtaba and Mirsadraee, Majid and Loghmani, Tina and Darabi, Azadeh and Derafshi, Raheleh and Behmadi, Maryam and Boskabadi, Abbas and Akhondian, Salehe and Eshraghi, Peyman and Hosseini, Mahya and Farhat, Ahmadshah and Ghane Sharbaf, Fatemeh and Norooziasl, Samaneh and Ghaemi, Nosrat and Ahangari, Najmeh and Etemadifar, Masoud and Moosavian, Toktam and Shervin Badv, Reza and Houlden, Henry and Sarraf, Payam and Haghighatzadeh, Mahsa and Heidari, Morteza and Ghayoor Karimiani, Ehsan},
title = {Bi-allelic TPP1 variants in neuronal ceroid lipofuscinosis 2: clinical findings from an Iranian cohort of 20 patients, founder effect, and in silico analyses},
journal = {Human Genetics},
year = {2026},
doi = {10.1007/s00439-025-02812-3}
}
EUVIMED